CN118541364A - 氨基吡唑化合物的用途 - Google Patents

氨基吡唑化合物的用途 Download PDF

Info

Publication number
CN118541364A
CN118541364A CN202280084861.5A CN202280084861A CN118541364A CN 118541364 A CN118541364 A CN 118541364A CN 202280084861 A CN202280084861 A CN 202280084861A CN 118541364 A CN118541364 A CN 118541364A
Authority
CN
China
Prior art keywords
compound
use according
formula
jak
months
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280084861.5A
Other languages
English (en)
Chinese (zh)
Inventor
L·霍斯泊尔
T·科瓦斯基
C·莫勒
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Intervet International BV
Original Assignee
Intervet International BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intervet International BV filed Critical Intervet International BV
Publication of CN118541364A publication Critical patent/CN118541364A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202280084861.5A 2021-12-24 2022-12-23 氨基吡唑化合物的用途 Pending CN118541364A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP21217736 2021-12-24
EP21217736.4 2021-12-24
PCT/EP2022/087698 WO2023118555A1 (en) 2021-12-24 2022-12-23 Use of aminopyrazole compounds

Publications (1)

Publication Number Publication Date
CN118541364A true CN118541364A (zh) 2024-08-23

Family

ID=79025165

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280084861.5A Pending CN118541364A (zh) 2021-12-24 2022-12-23 氨基吡唑化合物的用途

Country Status (9)

Country Link
US (1) US20250049775A1 (https=)
EP (1) EP4452970A1 (https=)
JP (1) JP2024545293A (https=)
KR (1) KR20240124925A (https=)
CN (1) CN118541364A (https=)
AU (1) AU2022418280A1 (https=)
CA (1) CA3242449A1 (https=)
MX (1) MX2024007863A (https=)
WO (1) WO2023118555A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4208157A1 (en) 2020-09-04 2023-07-12 Elanco Us Inc. Palatable formulations

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK286640B6 (sk) 1998-06-19 2009-03-05 Pfizer Products Inc. Pyrol [2,3-d] pyrimidínová zlúčenina, jej použitie na výrobu liečiva, farmaceutická kompozícia s jej obsahom, použitie jej kombinácie s ďalšími činidlami a súpravy s jej obsahom na výrobu liečiva
KR101335843B1 (ko) 2008-08-20 2013-12-02 조에티스 엘엘씨 피롤로[2,3-ｄ]피리미딘 화합물
CA2849168A1 (en) 2011-09-22 2013-03-28 Merck Sharp & Dohme Corp. Cycloalkylnitrile pyrazole carboxamides as janus kinase inhibitors
WO2014146246A1 (en) 2013-03-19 2014-09-25 Merck Sharp & Dohme Corp. Cycloalkyl nitrile pyrazolo pyridones as janus kinase inhibitors
JP7116063B2 (ja) 2016-12-14 2022-08-09 インターベット インターナショナル ベー． フェー． 選択的ヤヌスキナーゼ阻害剤としてのアミノピラゾール類
KR20220119024A (ko) * 2019-12-20 2022-08-26 인터벳 인터내셔널 비.브이. 피라졸 제약 조성물

Also Published As

Publication number Publication date
WO2023118555A1 (en) 2023-06-29
KR20240124925A (ko) 2024-08-19
EP4452970A1 (en) 2024-10-30
AU2022418280A1 (en) 2024-06-13
US20250049775A1 (en) 2025-02-13
JP2024545293A (ja) 2024-12-05
CA3242449A1 (en) 2023-06-29
MX2024007863A (es) 2024-08-30

Similar Documents

Publication Publication Date Title
AU2013205648B2 (en) Combination treatment
US10806735B2 (en) Use of neutrophil elastase inhibitors in liver disease
JP2018184440A (ja) うつ病の治療におけるスコポラミンおよびケタミンを含む組成物
JP2025092508A (ja) デクスメデトミジン製剤を使用する睡眠障害の予防または治療
US20240277673A1 (en) Methods of treating behavior alterations
ES2750662T3 (es) Orvepitant para el tratamiento del prurito crónico
WO2021016369A1 (en) Pimavanserin for trating schizophrenia or for treating psychosis secondary to neurodegenerative disorders or depressive disorder
US7989479B2 (en) Use of a p38 kinase inhibitor for treating psychiatric disorders
CN118541364A (zh) 氨基吡唑化合物的用途
KR101893551B1 (ko) 치료 방법
JP2024153742A (ja) Ｃｃｒ３阻害剤を用いて、加齢性機能障害を治療するための方法および組成物
RU2799049C2 (ru) Способы лечения изменений поведения
CA3071804C (en) Use of a kdm1a inhibitor in the treatment of behavior alterations
HK40122445A (en) Methods of treating behavior alterations
CA3040420A1 (en) Mast cell stabilizers for treatment of chronic inflammatory conditions
WO2025264695A1 (en) Compositions and methods for treatment
JP2004175786A (ja) Ｉ型アレルギー疾患治療用組成物
CN111432813A (zh) 用于预防、减轻、或治疗精神分裂症的包含氨基甲酸酯化合物的共混物

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination